在准人类表皮生长因子受体2-低乳腺癌的公开问题,当前的挑战和未来的前景
G Curigliano1, R Dent2, H Earle3
1European Institute of Oncology, IRCCS, Milan; Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.
ESMO open
|April 13, 2024
概括
大约60%的HER2阴性乳腺癌是HER2低的,可以用trastuzumab deruxtecan (T-DXd) 治疗. 准确的HER2评估对于识别符合条件的患者进行这种向治疗至关重要.
科学领域:
- 在瘤学瘤学.
- 医学诊断 医学诊断 医学诊断
- 药理学 药理学是指药理学的学科.
背景情况:
- 大约60%的HER2阴性乳腺癌呈现低HER2表达 (HER2-低).
- 低HER2的乳腺癌在激素受体阳性 (高达85%) 和三阴性 (高达63%) 亚型中普遍存在.
- DESTINY-Breast04试验证明了HER2-低瘤是可向的,导致T-DXd的批准.
研究的目的:
- 为识别HER2-低乳腺癌患者提供背景.
- 讨论HER2评估方法,评分和报告.
- 审查与T-DXd相关的不良事件管理.
主要方法:
- 对乳腺癌中HER2评估现有证据的审查.
- 对DESTINY-Breast04试验数据和T-DXd疗效的分析.
- 讨论HER2评分和解释方面的挑战.
主要成果:
- 特拉斯图祖马布德鲁克斯泰干 (T-DXd) 在HER2低乳腺癌患者 (IHC 1+或IHC 2+/ISH-) 中有效.
- 准确的HER2评估对于T-DXd资格至关重要.
- 在某些场景下,有可能对HER2状态进行重新评估.
结论:
- 低HER2乳腺癌是T-DXd的目标人群.
- 标准化的HER2评估对于最佳的患者选择至关重要.
- 目前正在进行的研究可能会完善患者的鉴定和治疗策略.
相关概念视频
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K